Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter

Oncology Research

Volumn 15, Issue 7-8, 2005, Pages 373-383

  Borgatti, Monica ^a   Boyd, Douglas D ^b   Lampronti, Ilaria ^a   Bianchi, Nicoletta ^a   Fabbri, Enrica ^a   Saviano, Michele ^c   Romanelli, Alessandra ^d   Pedone, Carlo ^c   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Gene therapy; Gene transcription; Peptide nucleic acids (PNA); PNA DNA chimeras; Sp1; Transcription factor decoy; Urokinase type plasminogen activator receptor (uPAR)

Indexed keywords

DNA; FIREFLY LUCIFERASE; PEPTIDE NUCLEIC ACID; TRANSCRIPTION FACTOR SP1; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL STRAIN HEPG2; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE;

EID: 32044434958     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005776449734     Document Type: Article

References (54)

1. de Bock, C. E.; Wang, Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24:13-39; 2004.
2. Andreasen, P. A.; Egelund, R.; Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:25-40; 2000.
3. Moriyama, T.; Kataoka, H.; Hamasuna, R.; Yoshida, E.; Sameshima, T.; Iseda, T.; Yokogami, K.; Nakano, S.; Koono, M.; Wakisaka, S. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin. Exp. Metastasis 17:873-879; 1999.
4. Okusa, Y.; Ichikura, T.; Mochizuki, H.; Shinomiya, N. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int. J. Oncol. 17:1001-1005; 2000.
5. Andreasen, P. A.; Egelund, R.; Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:25-40; 2000.
6. Hollas, W.; Soravia, E.; Mazar, A.; Henkin, J.; Blasi, F.; Boyd, D. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem. J. 285:629-634; 1992.
7. Bruckner, A.; Fielderman, A. E.; Kirchheimer, J. C.; Binder, B. R.; Remold, H. G. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res. 52:3043-3047; 1992.
8. Crowley, C. W.; Cohen, R. L.; Lucas, B. K.; Liu, G.; Shuman, M. A.; Levinson, A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90:5021-5025; 1993.
9. Pedersen, H.; Brinner, N.; Francio, D.; Osterlind, K.; Rìnne, E.; Hansen, H. H.; Dano, K.; Grìndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous- and large-cell lung-cancer tissue. Cancer Res. 54:4671-4675; 1994.
10. Stahl, A.; Mueller, B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:3066-3067; 1994.
11. Kobayashi, H.; Gotoh, J.; Fujie, M.; Shinohara, H.; Moniwa, N.; Terao, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 57:727-733; 1994.
12. Liu, G.; Shuman, M. A.; Cohen, R. L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60:501-506; 1995.
13. Kaneko, T.; Konno, H.; Baba, M.; Tanaka, T.; Nakamura, S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci. 94:43-49; 2003.
14. Nishimura, K.; Matsumiya, K.; Miura, H.; Tsujimura, A.; Nonomura, N.; Matsumoto, K.; Nakamura, T.; Okuyama, A. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells. Int. J. Androl. 26:175-179; 2003.
15. Vallera, D. A.; Li, C.; Jin, N.; Panoskaltsis-Mortari, A.; Hall, W. A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. 94:597-606; 2002.
16. Rabbani, S. A.; Gladu, J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 62:2390-2397; 2002.
17. Mohanam, S.; Jasti, S. L.; Kondraganti, S. R.; Chandrasekar, N.; Kin, Y.; Fuller, G. N.; Lakka, S. S.; Kyritsis, A. P.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Yung, W. K.; Rao, J. S. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin. Cancer Res. 7:2519-2526; 2001.
18. Soravia, E.; Grebe, A.; De Luca, P.; Helin, K.; Suh, T. T.; Degen, J. L.; Blasi, F. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 86:624-635; 1995.
19. Lengyel, E.; Wang, H.; Stepp, E.; Juarez, J.; Wang, Y.; Doe, W.; Pfarr, C. M.; Boyd, D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 271:23176-23184; 1996.
20. Dang, J.; Boyd, D.; Wang, H.; Allgayer, H.; Doe, W. F.; Wang, Y. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur. J. Biochem. 264:92-99; 1999.
21. Allgayer, H.; Wang, H.; Gallick, G. E.; Crabtree, A.; Mazar, A.; Jones, T.; Kraker, A. J.; Boyd, D. D. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J. Biol. Chem. 274:18428-18437; 1999.
22. Gambari, R. New trends in the development of transcription factor decoy (TFD) pharmacotherapy. Curr. Drug Targets 5:419-430; 2004.
23. Piva, R.; Gambari, R. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol. Cancer Res. Treat. 1:405-416; 2002.
24. Morishita, R. Perspective in progress of cardiovascular gene therapy. J. Pharmacol. Sci. 95:1-8; 2004.
25. Morishita, R.; Sugimoto, T.; Aoki, M.; Kida, I.; Tomita, N.; Moriguchi, A.; Maeda, K.; Sawa, Y.; Kaneda, Y.; Higaki, J.; Ogihara, T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med. 3:894-899; 1997.
26. Tomita, N.; Kim, J. Y.; Gibbons, G. H.; Zhang, L.; Kaneda, Y.; Stahl, R. A.; Ogborn, M.; Venderville, B.; Morishita, R.; Baran, D.; Dzau, V. J. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int. J. Mol. Med. 13:629-636; 2004.
27. Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497-1500; 1991.
28. Nielsen, P. E.; Egholm, M. An introduction to peptide nucleic acid. Curr. Issues Mol. Biol. 1:89-104; 1999.
29. Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier, S. M.; Driver, D. A.; Berg, R. H.; Kim, S. K.; Norden, B.; Nielsen, P. E. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365:566-568; 1993.
30. Gambari, R. Peptide-nucleic acids (PNAs): A tool for the development of gene expression modifiers. Curr. Pharm. Des. 7:1839-1862; 2001.
31. Saviano, M.; Romanelli, A.; Bucci, E.; Pedone, C.; Mischiati, C.; Bianchi, N.; Feriotto, G.; Borgatti, M.; Gambari, R. Computational procedures to explain the different biological activity of DNA/DNA, DNA/PNA and PNA/PNA hybrid molecules mimicking NF-kappaB binding sites. J. Biomol. Struct. Dyn. 18:353-362; 2000.
32. Demidov, V. V.; Potaman, V. N.; Frank-Kamenetskii, M. D.; Egholm, M.; Buchard, O.; Sonnichsen, S. H.; Nielsen, P. E. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. 48:1310-1313; 1994.
33. Betts, L.; Josey, J. A.; Veal, J. M.; Jordan, S. R. A nucleic acid triple helix formed by a peptide nucleic acid-DNA complex. Science 270:1838-1841; 1995.
34. Larsen, H. J.; Nielsen, P. E. Transcription-mediated binding of peptide nucleic acid (PNA) to double-stranded DNA: Sequence-specific suicide transcription. Nucleic Acids Res. 24:458-463; 1996.
35. Gambari, R. Biological activity and delivery of peptide nucleic acids (PNA) -DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr. Med. Chem. 11:1253-1263; 2004.
36. Romanelli, A.; Pedone, C.; Saviano, M.; Bianchi, N.; Borgatti, M.; Mischiati, C.; Gambari, R. Molecular interactions with nuclear factor kappaB (NF-kappaB) transcription factors of a PNA-DNA chimera mimicking NF-kappaB binding sites. Eur. J. Biochem. 268:6066-6075; 2001.
37. Borgatti, M.; Breda, L.; Cortesi, R.; Nastruzzi, C.; Romanelli, A.; Saviano, M.; Bianchi, N.; Mischiati, C.; Pedone, C.; Gambari, R. Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. Biochem. Pharmacol. 64:609-616; 2002.
38. Borgatti, M.; Lampronti, I.; Romanelli, A.; Pedon, C.; Saviano, M.; Bianchi, N.; Mischiati, C.; Gambari, R. Transcription factor decoy molecules based on a peptide nucleic acid (PNA) -DNA chimera mimicking Sp1 binding sites. J. Biol. Chem. 278:7500-7509; 2003.
39. Borgatti, M.; Romanelli, A.; Saviano, M.; Pedone, C.; Lampronti, I.; Breda, L.; Nastruzzi, C.; Bianchi, N.; Mischiati, C.; Gambari, R. Resistance of decoy PNA-DNA chimeras to enzymatic degradation in cellular extracts and serum. Oncol. Res. 13:279-287; 2003.
40. Dignam, J. D.; Lebovitz, R. M.; Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489; 1983.
41. Feriotto, G.; Finotti, A.; Volpe, P.; Treves, S.; Ferrari, S.; Angelelli, C.; Zorzato, F.; Gambari, R. MEF-2 activates promoter sequences of the human AβH-J-J locus, encoding aspartyl-β-hydroxylase, junctin and junctate. Mol. Cell. Biol. 25:3261-3275; 2005.
42. Hall, J. M.; McDonnel, D. P.; Korach, K. S. Allosteric regulation of estrogen receptor structure, function and co-activator recruitment by different estrogen response elements. Mol. Endocrinol. 16:469-486; 2002.
43. Cohn, M. A.; Hjelmso, I.; Wu, L. C.; Guldberg, P.; Lukanidin, E. M.; Tulchinsky, E. M. Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer. Nucleic Acids Res. 29:3335-3346; 2001.
44. Lang, J. C.; Whitelaw, B.; Talbot, S.; Wilkie, N. M. Transcriptional regulation of the human c-myc gene. Br. J. Cancer 9:62-66; 1988.
45. Black, A. R.; Black, J. D.; Azizkhan-Clifford, J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188:143-160; 2001.
46. Chae, Y. M.; Park, K. K.; Magae, J.; Lee, I. S.; Kim, C. H.; Kim, H. C.; Hong, S.; Lee, J. G.; Choi, I. J.; Kim, H. S.; Min, K. S.; Lee, I. K.; Chang, Y. C. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem. Biophys. Res. Commun. 319:50-55; 2004.
47. Novak, E. M.; Metzger, M.; Chammas, R.; da Costa, M.; Dantas, K.; Manabe, C.; Pires, J.; de Oliveira, A. C.; Bydlowski, S. P. Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther. 10:1992-1997; 2003.
48. Ishibashi, H.; Nakagawa, K.; Onimaru, M.; Castellanous, E. J.; Kaneda, Y.; Nakashima, Y.; Shirasuna, K.; Sueishi, K. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res. 60:6531-6536; 2000.
49. Mischiati, C.; Sereni, A.; Finotti, A.; Breda, L.; Cortesi, R.; Nastruzzi, C.; Romanelli, A.; Saviano, M.; Bianchi, N.; Pedone, C.; Borgatti, M.; Gambari, R. Complexation to cationic microspheres of double-stranded peptide nucleic acid-DNA chimeras exhibiting decoy activity. J. Biomed. Sci. 11:697-704; 2004.
50. Nair, R. R.; Wang, H.; Fokt, I.; Priebe, W.; Boyd, D. D. A bisanthracycline (WP631) represses u-PAR gene expression and cell migration by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol. Res. 15:265-279; 2005.
51. Shetty, S.; Idell, S. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J. Biol. Chem. 276:24549-24556; 2001.
52. Novak, E. M.; Metzger, M.; Chammas, R.; da Costa, M.; Dantas, K.; Manabe, C.; Pires, J.; de Oliveira, A. C.; Bydlowski, S. P. Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther. 10:1992-1997; 2003.
53. Park, I. K.; Lyu, M. A.; Yeo, S. J.; Han, T. H.; Kook, Y. H. Sp1 mediates constitutive and transforming growth factor beta-inducible expression of urokinase type plasminogen activator receptor gene in human monocyte-like U937 cells. Biochim. Biophys. Acta 1490:302-310; 2000.
54. Hata, Y.; Duh, E.; Zhang, K.; Robinson, G. S.; Aiello, L. P. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J. Biol. Chem. 273:19294-19303; 1998.